Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study to Determine the Maximum Tolerated Dose and Evaluate Safety, Tolerability, and Pharmacokinetics of NM6603 in Patients With Advanced Solid Tumors

NCT06046066 is registered in ClinicalTrials.gov with NucMito Pharmaceuticals Co. Ltd. as lead sponsor.

NCT NCT06046066
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06046066 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study to Determine the Maximum Tolerated Dose and Evaluate Safety, Tolerability, and Pharmacokinetics of NM6603 in Patients With Advanced Solid Tumors
Lead sponsor
NucMito Pharmaceuticals Co. Ltd.
Phase
Phase 1
Overall status
Terminated
Start date
August 31, 2023
Completion date
April 25, 2025
Enrollment
17 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

cancers